Oily fish cut AMD risk by 50%

Article

Eating oily fish just once a week may cut the risk of developing wet age-related macular degeneration (AMD) by half, according to results of the EUREYE study, published in the August 2008 issue of the American Journal of Clinical Nutrition.

Eating oily fish just once a week may cut the risk of developing wet age-related macular degeneration (AMD) by half, according to results of the EUREYE study, published in the August 2008 issue of the American Journal of Clinical Nutrition.

Astrid Fletcher, Professor of Epidemiology at the London School of Hygiene & Tropical Medicine, UK and colleagues conducted a multicentre control study evaluating the relationship between oily fish (omega 3) consumption and AMD incidence. The team conducted a questionnaire on dietary habits and correlated the results with food composition tables, looking specifically at the levels of docosahexaenoicacid (DHA) and eicosapentaenoic acid (EPA) in the diets of wet AMD sufferers compared with the control group.

The team found that subjects who consumed omega 3-rich oily fish, such as salmon, trout and swordfish, once weekly, were 50% less likely to develop wet AMD than those who consume it more rarely, although these risk reduction benefits did not extend to non-oily white fish, such as cod, haddock and sea bass. High levels of DHA and EPA showed a statistically significant correlation to low incidences of wet AMD. The team did not investigate the impact of omega 3 nutritional supplements.

The researchers concluded, in results consistent with those that have previously been achieved in the US and Australia, that omega 3 derived from dietary oily fish reduces the risk of wet AMD.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.